Business
Todos Medical to Host Third Quarter 2022 Earnings and Business Update Conference Call on November 15, 2022
Todos Medical to Host Third Quarter 2022 Earnings and Business Update Conference Call on November 15, 2022.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n NEW YORK, NY, AND TEL AVIV, ISRAEL, Nov. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it will host the third quarter of 2022 earnings and business update conference call on November 15th, 2022 at 8:30am ET. Conference Call Details Time: Tuesday, November 15, 2022 at 8:30am ET Link: https://audience.mysequire.com/webinar-view?webinar_id=c823522b-146b-4b30-8243-3e16afc4ac24 Optional Dial-In: +1-346-248-7799 Meeting ID: 93308656732 Passcode: 151033 To learn more about the 3CL protease in SARS-CoV-2 replication, please visit www.3clpro.com. To purchase Tollovid please visit Amazon or www.MyTollovid.com. About Todos Medical Ltd. Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that examines cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally developed cancer-screening tests, TMB-1 and TMB-2 have received a CE mark in Europe. Todos recently acquired U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing, Long COVID Panel analyses, and Provista's proprietary commercial-stage Videssa® breast cancer blood test. More information on Provista is available at www.provistadx.com. Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphoc...